跳至主要内容
临床试验/NCT02682576
NCT02682576已完成不适用

Brachial Artery Ultrasound Imaging: A Repeatability Study

Everist Genomics, Inc4 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2016年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
21
试验地点
4
主要终点
Change from baseline % flow-mediated dilation (%FMD) at 1 hour

研究概览

简要总结

The objective of the study is to define the analytical repeatability of quantifying flow-mediated dilation of the brachial artery using brachial artery ultrasound imaging using upper arm cuff occlusion.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women, ≥18 years old
  • Eastern Cooperative Oncology Group/Zubrod score performance status of 0, 1, or 2, determined within 7 days prior to FMD testing on Study Day 1 (Visit 1)
  • Written informed consent understood and signed; understanding of study procedures and ability to comply with them for the length of the study

排除标准

  • Body mass index (BMI) >50 kg/m2
  • Mid-upper arm circumference of arm selected for FMD testing <17 cm or >42 cm
  • Sinus arrhythmia (RR intervals vary by >50%), atrial fibrillation, atrial flutter, multifocal atrial tachycardia, frequent (>1 per 10-sec strip) premature atrial or ventricular contractions (isolated, non-isolated, or alternating), documented by 12-lead ECG with rhythm strip at the time of subject screening.
  • Clinical signs and/or symptoms of active viral or bacterial infections
  • Resting tremor or inability to remain still for the duration of the testing period
  • Systolic blood pressure (SBP) at rest of >170 mmHg or diastolic blood pressure (DBP) at rest of ≥110 mmHg.
  • Diabetic subjects - Type I or II
  • Previous intolerable adverse reaction(s) to vascular testing using an upper extremity occlusive pneumatic cuff

结局指标

主要结局

Change from baseline % flow-mediated dilation (%FMD) at 1 hour

时间窗: 1 hour

Repeat brachial artery ultrasound imaging of the same subject after 1 hour using the same operator and vascular ultrasound equipment

次要结局

  • Incidence of emergent adverse device effects (ADEs) according to CTCAE v4.03(1 day)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验